This study is currently not recruiting participants.

Topiramate as a disease modifying therapy for Neuropathy

  • STATUS
    Not Recruiting
  • participants needed
    10
Send
Updated on 19 February 2024

Summary

NN108 Topiramate as a disease modifying therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)
The University of Pennsylvania is currently looking for people with Cryptogenic Sensory Peripheral Neuropathy for a research study conducted by the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT). Dr. Gordon Smith (Virginia Commonwealth University) is leading this national study. The National Institutes of Health (NIH) is supporting the study.

Description

The purpose of the research study is to learn if the drug topiramate slows the progression of Cryptogenic Sensory Peripheral Neuropathy (CSPN) (also known as “idiopathic neuropathy”) and improves quality of life. As part of this study, we will use a number of assessments and questionnaires to determine if topiramate improves symptoms of CSPN. There is a one in two chance of receiving the study drug or placebo pill.
 
Participants must be between 18-80 years of age to be in the study, have a diagnosis of CSPN, have metabolic syndrome, and no history of prior therapy with topiramate.

FAQ

This study is no longer enrolling participants.

Details
Condition Neuropathy,Idiopathic Neuropathy,Cryptogenic Sensory Peripheral Neuropathy,CSPN
Age 18years - 80years
Clinical Study IdentifierNCT02878798
Last Modified on19 February 2024

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.